Butanedioic acid, sulfo-, 1,4-dioctyl ester, potassium salt | 72102-49-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Butanedioic acid, sulfo-, 1,4-dioctyl ester, potassium salt
• 英文别名: potassium;1,4-dioctoxy-1,4-dioxobutane-2-sulfonate
• CAS: 72102-49-9
• 化学式: C20H37KO7S
• 分子量: 460.7
• InChiKey: IITZOMUJXICGGH-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  29
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  118
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF
  申请人：Manning David D.

  公开号：US20090298809A1

  公开（公告）日：2009-12-03

  Novel 5-HT 3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention.

  揭示了新型5-HT3受体调节剂。这些化合物用于治疗各种疾病，包括化疗诱发的恶心和呕吐、术后恶心和呕吐以及肠易激综合征。本发明还描述了制备这些化合物的方法。
• [EN] COMBINATION THERAPY FOR CONSTIPATION COMPRISING A LAXATIVE AND A PERIPHERAL OPIOID ANTAGONIST<br/>[FR] TRAITEMENT COMBINE DE LA CONSTIPATION COMPRENANT UN LAXATIF ET UN ANTAGONISTE DES OPIOIDES A ACTION PERIPHERIQUE
  申请人：PROGENICS PHARM INC

  公开号：WO2004091665A1

  公开（公告）日：2004-10-28

  Methods for treating constipation are provided. The methods include administration of peripheral opioid antagonists in combination with laxatives and/or stool softeners. Patients treatable by the invention include those refractory to conventional laxative and stool softener therapy.

  提供了治疗便秘的方法。这些方法包括在使用泻药和/或软便剂的同时，给予外周阿片受体拮抗剂。本发明可治疗那些对传统泻药和软便剂疗法无效的患者。
• SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR TREATING DIABETES
  申请人：Dalton James T.

  公开号：US20130034562A1

  公开（公告）日：2013-02-07

  This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.

  本发明提供了一种使用SARM化合物或包含该化合物的组合物来治疗和预防非小细胞肺癌（NSCLC）患者的肌肉消耗；治疗癌症患者的早期消瘦或恶病质（预防肌肉消耗）；治疗和预防由癌症或癌症治疗引起的身体机能丧失；增加身体机能；并提高NSCLC患者的生存率，其中患者接受癌症治疗。
• SELECTIVE ANDROGEN RECEPTOR MODULATOR AND METHODS OF USE THEREOF
  申请人：UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

  公开号：US20160166530A1

  公开（公告）日：2016-06-16

  This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.

  本发明提供了取代的酰基苯胺化合物及其在治疗受试者中的各种疾病或病况中的应用，包括但不限于肌肉消耗病和/或疾病，如杜氏肌肉萎缩症或贝克肌肉萎缩症。
• Sustained release pharmaceutical formulation for inhalation
  申请人：——

  公开号：US20040105821A1

  公开（公告）日：2004-06-03

  Pharmaceutical formulations and methods are provided for the sustained delivery of a pharmaceutical agent to the lungs of a patient by inhalation. The formulation includes porous microparticles which comprise a pharmaceutical agent and a matrix material, wherein upon inhalation of the formulation a therapeutically or prophylactically effective amount of the pharmaceutical agent is released from the microparticles in the lungs for at least 2 hours. Preferably, a majority of the pharmaceutical agent is released from the microparticles by 24 hours following inhalation, for example where a majority of the pharmaceutical agent is released no earlier than about 2 hours and no later than about 24 hours following inhalation. Methods for delivering a pharmaceutical agent, such as a corticosteroid, to the lungs of a patient are also provided. For example, the method includes having the patient inhale a dry powder blend comprising the present microparticles and a pharmaceutically acceptable bulking agent.

  提供了一种药物制剂和方法，通过吸入将药物剂量持续释放到患者的肺部。该制剂包括多孔微粒，其中包括药物剂量和基质材料，吸入该制剂后，肺部至少释放出治疗或预防有效剂量的药物剂量，持续时间至少为2小时。最好，药物剂量的大部分在吸入后的24小时内从微粒中释放出来，例如，药物剂量的大部分在吸入后不早于约2小时，不晚于约24小时内释放。还提供了将药物剂量（例如皮质类固醇）传递到患者肺部的方法。例如，该方法包括让患者吸入包括当前微粒和药用可接受的增容剂的干粉混合物。